Pharmacoeconomic analysis of treatment of children with acute lymphoblastic leukemia according to ALL-MB-2002 protocol

Comparative pharmacoeconomic analysis of treatment according to ALL-MB-2002 protocol between two groups of children with acute lymphoblastic leukemia (ALL) (n=53) depending on use of intravenous immunoglobulin (IVIG) aiming to infectious complications preventing was conducted. It is shown, that actu...

Full description

Saved in:
Bibliographic Details
Main Authors: N. V. Miga, A. S. Shmargun, O. V. Aleinikova
Format: Article
Language:Russian
Published: ABV-press 2022-11-01
Series:Онкогематология
Subjects:
Online Access:https://oncohematology.abvpress.ru/ongm/article/view/774
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Comparative pharmacoeconomic analysis of treatment according to ALL-MB-2002 protocol between two groups of children with acute lymphoblastic leukemia (ALL) (n=53) depending on use of intravenous immunoglobulin (IVIG) aiming to infectious complications preventing was conducted. It is shown, that actual protocol cost in group of children treating with IVIG in 1,5 times low (р<0,001). Price reduction of medicamentous treatment in this group of patients occur due to reduction of complications treatment cost, p<0,001. Decreasing time of treatment interruptions in group of patients with IVIG result in severe reduction of hospitalization cost (p<0,001). Application of this drug is more economic because of almost in 2 times reduction cost/efficiency ratio and 1,4 times increasing of additional years of life in ALL patients.
ISSN:1818-8346
2413-4023